CIP2A overexpression is associated with c-Myc expression in colorectal cancer

References

• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69 - 90; http://dx.doi.org/10.3322/caac.20107; PMID: 21296855
   PubMed Web of Science ®Google Scholar
• Center MM, Jemal A, Ward E. International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev 2009; 18:1688 - 94; http://dx.doi.org/10.1158/1055-9965.EPI-09-0090; PMID: 19505900
   PubMed Web of Science ®Google Scholar
• Ferrari P, Jenab M, Norat T, Moskal A, Slimani N, Olsen A, et al. Lifetime and baseline alcohol intake and risk of colon and rectal cancers in the european prospective investigation into cancer and nutrition (EPIC). Int J Cancer 2007; 121:2065 - 72; http://dx.doi.org/10.1002/ijc.22966; PMID: 17640039
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319:525 - 32; http://dx.doi.org/10.1056/NEJM198809013190901; PMID: 2841597
   PubMed Web of Science ®Google Scholar
• Pritchard CC, Grady WM. Colorectal cancer molecular biology moves into clinical practice. Gut 2011; 60:116 - 29; http://dx.doi.org/10.1136/gut.2009.206250; PMID: 20921207
   PubMed Web of Science ®Google Scholar
• Junttila MR, Puustinen P, Niemelä M, Ahola R, Arnold H, Bottzauw T, et al. CIP2A inhibits PP2A in human malignancies. Cell 2007; 130:51 - 62; http://dx.doi.org/10.1016/j.cell.2007.04.044; PMID: 17632056
   PubMed Web of Science ®Google Scholar
• Li W, Ge Z, Liu C, Liu Z, Bjorkholm M, Jia J, et al. CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells. Clin Cancer Res 2008; 14:3722 - 8; http://dx.doi.org/10.1158/1078-0432.CCR-07-4137; PMID: 18559589
   PubMed Web of Science ®Google Scholar
• Katz J, Jakymiw A, Ducksworth MK, Stewart CM, Bhattacharyya I, Cha S, et al. CIP2A expression and localization in oral carcinoma and dysplasia. Cancer Biol Ther 2010; 10:694 - 9; http://dx.doi.org/10.4161/cbt.10.7.12895; PMID: 21068540
   PubMed Web of Science ®Google Scholar
• Vaarala MH, Vaisanen MR, Ristimäki A. CIP2A expression is increased in prostate cancer. J Exp Clin Cancer Res 2010; 29:136; http://dx.doi.org/10.1186/1756-9966-29-136; PMID: 20964854
   PubMed Web of Science ®Google Scholar
• Qu W, Li W, Wei L, Xing L, Wang X, Yu J.. CIP2A is overexpressed in esophageal squamous cell carcinoma. Med Oncol 2010; In press http://dx.doi.org/10.1007/s12032-010-9768-9; PMID: 21140243
   PubMed Web of Science ®Google Scholar
• Wang J, Li W, Li L, Yu X, Jia J, Chen C.. CIP2A is over-expressed in acute myeloid leukaemia and associated with HL60 cells proliferation and differentiation. Int J Lab Hematol 2011; 33:290 - 8; http://dx.doi.org/10.1111/j.1751-553X.2010.01288.x; PMID: 21219591
   PubMed Web of Science ®Google Scholar
• Khanna A, Böckelman C, Hemmes A, Junttila MR, Wiksten JP, Lundin M, et al. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst 2009; 101:793 - 805; http://dx.doi.org/10.1093/jnci/djp103; PMID: 19470954
   PubMed Web of Science ®Google Scholar
• Dong QZ, Wang Y, Dong XJ, Li ZX, Tang ZP, Cui QZ, et al. CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis. Ann Surg Oncol 2011; 18:857 - 65; http://dx.doi.org/10.1245/s10434-010-1313-8; PMID: 20842459
   PubMed Web of Science ®Google Scholar
• Böckelman C, Hagström J, Mäkinen LK, Keski-Säntti H, Häyry V, Lundin J, et al. High CIP2A immunoreactivity is an independent prognostic indicator in early-stage tongue cancer. Br J Cancer 2011; 104:1890 - 5; http://dx.doi.org/10.1038/bjc.2011.167; PMID: 21610708
   PubMed Web of Science ®Google Scholar
• Böckelman C, Lassus H, Hemmes A, Leminen A, Westermarck J, Haglund C, et al. Prognostic role of CIP2A expression in serous ovarian cancer. Brit J Cancer 2011; 105:989 - 95; http://dx.doi.org/10.1038/bjc.2011.346; PMID: 21897396
   PubMed Web of Science ®Google Scholar
• Côme C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X, et al. CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res 2009; 15:5092 - 100; http://dx.doi.org/10.1158/1078-0432.CCR-08-3283; PMID: 19671842
   PubMed Web of Science ®Google Scholar
• Wang WS, Chen PM, Chiou TJ, Liu JH, Lin JK, Lin TC, et al. Epidermal growth factor receptor R497K polymorphism is a favorable prognostic factor for patients with colorectal carcinoma. Clin Cancer Res 2007; 13:3597 - 604; http://dx.doi.org/10.1158/1078-0432.CCR-06-2601; PMID: 17575224
   PubMed Web of Science ®Google Scholar
• Liu Y, Yang Y, Xu H, Dong X. Implication of USP22 in the regulation of BMI-1, c-myc, p16INK4a, p14ARF, and cyclin D2 expression in primary colorectal carcinomas. Diagn Mol Pathol 2010; 19:194 - 200; http://dx.doi.org/10.1097/PDM.0b013e3181e202f2; PMID: 21052002
   PubMed Web of Science ®Google Scholar
• Grady WM, Markowitz SD. Genetic and epigenetic alterations in colon cancer. Annu Rev Genomics Hum Genet 2002; 3:101 - 28; http://dx.doi.org/10.1146/annurev.genom.3.022502.103043; PMID: 12142355
   PubMed Web of Science ®Google Scholar
• Khanna A, Okkeri J, Bilgen T, Tiirikka T, Vihinen M, Visakorpi T, et al. ETS1 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells. PLoS ONE 2011; 6:e17979; http://dx.doi.org/10.1371/journal.pone.0017979; PMID: 21445343
   PubMedGoogle Scholar
• Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, Kochli OR, et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 2001; 159:2249 - 56; http://dx.doi.org/10.1016/S0002-9440(10)63075-1; PMID: 11733374
   PubMed Web of Science ®Google Scholar
• Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4:844 - 7; http://dx.doi.org/10.1038/nm0798-844; PMID: 9662379
   PubMed Web of Science ®Google Scholar
• Kallioniemi OP, Wagner U, Kononen J, Sauter G. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 2001; 10:657 - 62; http://dx.doi.org/10.1093/hmg/10.7.657; PMID: 11257096
   PubMed Web of Science ®Google Scholar
• Soo Hoo L, Zhang JY, Chan EK. Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer. Oncogene 2002; 21:5006 - 15; http://dx.doi.org/10.1038/sj.onc.1205625; PMID: 12118381
   PubMed Web of Science ®Google Scholar